Floatz logo

Bacitracin

Metabolic Syndrome (MetS)

Catholic University of the Sacred HeartmixtureN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Metabolic Syndrome (MetS) cohort.

Asset / SponsorPhaseRating
Ezetimibe
NewAmsterdam Pharma
Phase 3B
Vancomycin
Catholic University of the Sacred Heart
N/AD
NEOMYCIN
Catholic University of the Sacred Heart
N/AD

Same molecule, other indications

Bacitracin is also rated in:

skin carcinomaDormant
B
Indicative ·
57 / 100
View asset →
Primary Sclerosing Cholangitis (PSC)Dormant
CCC
Indicative ·
53 / 100
View asset →
Inflammatory Bowel Disease (IBD)Dormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →